Neogen (NEOG) Beats Q3 Earnings and Revenue Estimates
Neogen (NEOG) delivered earnings and revenue surprises of +125.00% and +3.30%, respectively, for the quarter ended February 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1d ago
More News
Envista Schedules First Quarter 2026 Earnings Call
Envista Schedules First Quarter 2026 Earnings Call Envista Schedules First Quarter 2026 Earnings Call PR Newswire BREA, Calif., April 8, 2026 BREA, Calif., April 8, 2026 /PRNewswire/ -- Envista...
PR Newswire·2d ago
Envista (NYSE:NVST) Lowered to "Hold" Rating by Zacks Research
Zacks Research lowered Envista from a "strong-buy" rating to a "hold" rating in a research note on Monday...
MarketBeat·2d ago
Reasons to Add Veeva Systems Stock to Your Portfolio for Now
VEEV's strong Q4, expanding AI strategy and major life sciences partnerships fuel growth despite rising costs.
Zacks·3d ago
Rigetti Delivers Novera QPU to USask for Quantum System Build
RGTI delivers a 9-qubit Novera QPU to USask, expanding its academic footprint and advancing modular quantum system adoption.
Zacks·4d ago
Here's Why Envista (NVST) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·4d ago
Tempus AI Stock Gains Following the ALERT Trial Result Announcement
TEM jumps after ALERT trial shows EHR alerts boost timely valve care, improving evaluations and interventions for aortic stenosis and MR patients.
Zacks·8d ago
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q4 results, though data security threats remain a key risk.
Zacks·8d ago
Cardinal Health Expands Ac-225 Capacity to Boost Cancer Therapies
CAH expands Ac-225 capacity, boosting its role in radiopharma as rising clinical demand and future cancer therapy commercialization drive growth.
Zacks·8d ago
Should You Continue to Retain Bruker Stock in Your Portfolio?
BRKR faces macro and currency headwinds, but strong BSI Nano growth, AI-driven demand and BioSpin innovations support its long-term outlook.